Compassionate Use Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials
| Status: | Enrolling by invitation |
|---|---|
| Conditions: | Blood Cancer, Lymphoma, Lymphoma |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 12/6/2018 |
| Start Date: | June 28, 2017 |
| End Date: | December 2024 |
An Open Label Compassionate Use Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials With B-cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
This is an open label compassionate use trial of Ublituximab and TGR-1202 in combination or
as single agents in patients currently receiving treatment on Ublituximab and/or TGR-1202
trials with B-cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia.
as single agents in patients currently receiving treatment on Ublituximab and/or TGR-1202
trials with B-cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia.
Inclusion Criteria:
- Subjects must be currently receiving treatment with ublituximab and/or TGR-1202 on a
previously approved protocol.
- Subjects must have completed at least 6 cycles of therapy on their current protocol.
Exclusion Criteria:
- Subject progressed while receiving therapy with ublituximab and/or TGR-1202 while
participating in their immediate previous trial.
We found this trial at
9
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials